@article{ATM17352,
author = {Rikke Borg and Frederik Persson},
title = {Empagliflozin reduces albuminuria—a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial},
journal = {Annals of Translational Medicine},
volume = {5},
number = {23},
year = {2017},
keywords = {},
abstract = {Nowadays, type 2 diabetes care covers much more than lowering of blood glucose. To prevent and treat both micro- and macrovascular complications, risk factors like blood pressure and dyslipidemia are equally important treatment targets.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/17352}
}